Thyroid metastases from breast carcinoma: case report and review of literature

Yichao Wang  
Sichuan University West China Hospital

Shengliang Zhou  
Sichuan University West China Hospital

Boyang Yu  
Sichuan University West China Hospital

Ping Zhou  
Sichuan University West China Hospital

Zhihui Li  
Sichuan University West China Hospital

Jingqiang Zhu  
Sichuan University West China Hospital

Tao Wei (✉️ taoweiweitaowt@163.com)  
Sichuan University West China Hospital

Case Report

Keywords: thyroid metastases, breast carcinoma, diagnosis, therapy, immunohistochemistry

DOI: https://doi.org/10.21203/rs.3.rs-45880/v1

License: ☺️️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Rationale: The thyroid is a rare site for distant metastases from breast carcinoma. The incidence of thyroid metastases in fine needle aspiration biopsy (FNAB) was less than 0.2%.

Patient concerns: We report a case of 54-year-old woman with a history of breast carcinoma presented with diffuse scattered microcalcifications in thyroid and enlarged bilateral cervical lymph nodes detected on ultrasound (US). Physical examination of the patient revealed stiff and enlarged thyroid lobes.

Diagnoses: FNAB and immunohistochemistry (IHC) of the thyroid lesion confirmed the thyroid metastases from breast cancer.

Interventions and outcomes: Due to the comorbidities of breast carcinoma metastases to the right axillary, cervical lymph nodes and left chest wall, the patient received chemotherapy. After a follow-up of 10 months, the patient was alive without any new distant metastases.

Lessons: Our case highlights that thyroid metastases should be considered in a patient combined with thyroid lesions and a history of breast carcinoma. IHC played an important role in differentiating thyroid metastases from primary thyroid cancer.

1. Introduction

Thyroid metastases from breast cancer are unusual, accounting for less than 0.2% of thyroid fine needle aspiration biopsy (FNAB)[1, 2]. It is well known that the most frequent distant metastases of breast cancer are bone and visceral organs[3]. Generally, the common origins of thyroid metastases seems to be breast cancer and lung cancer in autopsy cases [4]. However, in clinical cases, the most common primary site is the kidney, followed by the breast[5, 6]. Recently, with the advent of advanced diagnostic methods such as FNAB and immunohistochemistry (IHC), thyroid metastases have been reported increasingly. Although FNAB can help evaluate benign and malignant thyroid lesions, it may be inefficient in differentiating metastatic thyroid lesion by FNAB. Therefore, IHC plays an important role in distinguishing thyroid metastases from primary thyroid cancer.

Here, we presented a case of thyroid metastases from breast carcinoma diagnosed by FNAB and immunohistochemistry.

2. Case Report

A 54 year old woman presented to the West China Hospital, Sichuan University for evaluation of the thyroid nodule and enlarged bilateral cervical lymph nodes detected on ultrasound (US). She denied any symptoms related to the thyroid disease. She had a personal history of invasive ductal carcinoma in the left breast (ER negative, PR negative, GATA3 positive and HER2 positive). She underwent left mastectomy and axillary lymphadenectomy, followed by chemotherapy with epirubicin, cyclophosphamide,
dexrazoxane, and trastuzumab. A core needle biopsy of right axillary adenopathy and mass in the left chest wall revealed metastatic breast carcinoma 2 years after surgery.

On physical examination of the thyroid, stiff and enlarged thyroid lobes were identified. A 1 cm mass in the upper outer quadrant of the right breast and a 5 cm mass in the left chest wall were found. A 2 cm right axillary adenopathy were found. There were no palpable lymph nodes in the cervical region.

US showed heterogeneous enlargement and diffuse scattered microcalcifications in both lobes of the thyroid (Fig. 1). A 0.7 cm hypoechogenic, well circumscribed nodule was also found in the left lobe of the thyroid. Right axillary and bilateral cervical lymph nodes were detected on US. Thyroid function was normal.

FNAB of bilateral lobes of the thyroid (Fig. 2) and cervical lymph nodes demonstrated malignant epithelial cells. Immunohistochemical staining of thyroid (Fig. 3), which exhibited positive GATA3 and HER2, and negative TTF1, TG, GCDFP15, PR and ER, confirmed breast carcinoma metastases to the thyroid.

Computed tomography (CT) showed no evidence of metastatic lesion in the brain, lung, liver and bone. Given the comorbidities of right axillary adenopathy and left chest wall metastases, the patient received chemotherapy. Because of financial difficulties, paclitaxel liposome and trastuzumab were administered in the patient. At the follow-up, the patient was alive at 10 months post-thyroid metastases diagnosis. Assessment by CT did not reveal any new distant metastases.

This study was approved by the ethics committee of the West China Hospital, Sichuan University, and written informed consent was provided by the patient for publication of this case publication.

3. Discussion

To the best of our knowledge, the thyroid is an uncommon site of metastatic cancer. This may be attributed to the fast blood flow of thyroid, abundant oxygen and iodine [7]. The incidence of thyroid metastases ranges from 1.25–24% in autopsy studies[8]. But the incidence of thyroid metastases was lower in clinical series than autopsy studies[1, 9]. It has been demonstrated that breast was the secondly frequent primary cancer site for thyroid metastases. [3, 9] Currently, the etiology of thyroid metastases from primary carcinoma is not clarified. One study speculated that decreased oxygen and iodine resulted by local thyroid diseases (i.e. thyroiditis and goiter) may contribute to the genesis of thyroid metastases[10].

The clinical presentation of thyroid metastases from breast cancer were similar to primary thyroid cancer, such as no symptoms, palpable neck mass, thyroid lesions detected on imaging examination and compression symptoms. Some studies reported that patients with thyroid metastases from breast cancer were symptomless and presented malignant thyroid nodules by ultrasound [1, 3]. Similar clinical manifestations were reported by Owens et al[11] and Pensabene et al[4]. In our case, the patient also
presented no symptoms related to the thyroid disease. Other studies showed patients with thyroid metastases from breast cancer demonstrated dysphagia and dyspnea[5–8]. In addition, the US features of thyroid metastases from breast cancer are not specific. Zhou et al[1] reported that six patients showed heterogeneous echogenicity with scattered microcalcification, and two patients had hypoechoic solid nodule on US. Pensabene et al[4] reported that one case showed enlarged thyroid with thyroid nodules on US. Similar thyroid nodule on US was reported by Magers et al[6], Lacka et al[7] and Owens et al[11]. Above US features also seen in our case. Therefore, there are no specific properties that clinically distinguish thyroid metastases from primary thyroid cancer.

Cytologic examination using FNAB is highly sensitive and specific in demonstrating a malignant thyroid nodule. But it is sometimes difficult to show the origin of the metastatic cancer[4]. Owens et al [11] reported that FNAB of thyroid metastases from breast cancer demonstrated malignant epithelial cells with enlarged nuclei and irregular nuclear contours, but in the absence of intranuclear grooves and pseudoinclusions. Magers et al [6] found that metastatic thyroid cancer from breast cancer can cytologically and morphologically mimic primary thyroid cancer on FNAB. Additionally, metastatic breast cancer cells in the thyroid, which mimicked C cell hyperplasia and medullary thyroid carcinoma, were observed in the case of Ghias et al[5]. In our case, FNAB of thyroid showed malignant cells with enlarged nuclei.

It has been documented that immunohistochemical stains can play a critical role in differentiating between thyroid metastases and primary thyroid cancer[12]. As noted, primary differentiated thyroid cancer commonly is TG, TTF-1 and PAX8 positive[12]. Calcitonin, involved in the parafollicular cells, is associated with medullary thyroid carcinoma[13]. In contrast, above immunohistochemical markers were negative for thyroid metastases[5, 14]. On the other hand, considering the history of breast cancer, the immunoprofile of breast cancer such as ER, PR, HER2, GATA3 and GCDFP15, should be used to confirm the origin from breast cancer metastasis. Previous studies have demonstrated that GATA3 and GCDFP15 expression were positively associated with breast carcinoma and breast cancer metastasis[15, 16]. GATA3 is superior to GCDFP15 in determining the breast origin[17, 18]. Ghias et al[5] reported that thyroid metastases cells were positive for ER, GATA3, and were negative for GCDFP, TTF-1, TG and calcitonin. Similar result is also observed in our case. Bourcier et al. [19] showed thyroid metastases from the breast cancer was positive for ER, PR and GATA3, but negative for HER2, TTF-1, PAX8 and calcitonin. In addition, GATA-3 (+), ER (+), PAX-8 (-) and TTF-1(-) in thyroid metastases cells were reported by Magers et al[6].

For the treatment and prognosis of thyroid metastases from breast cancer, Surgery for thyroid metastases is debatable. Some authors stated that thyroidectomy seem to be effective for alleviating dysphagia and dysphonia resulted by large metastatic thyroid lesions[5, 20, 21]. Thyroidectomy was recommended for isolated thyroid metastases from breast carcinomas[10]. Other cases suggested that thyroidectomy has no efficacy in patients with thyroid metastases from breast cancer combined with multiple distant metastases and chemotherapies should be performed[1, 4]. With the limitation of the small number of patient data, there is no definitive evidence to support surgery or chemotherapy or radiotherapy for thyroid metastases from breast cancer [4]. In addition, several studies have suggested
that the prognosis of thyroid metastases is poor[10]. Zhou et al[1] reported that 2 of 8 patients with thyroid metastases from breast cancer died at less than 22 months post-thyroid metastases diagnosis. Kim et al[3] reported 1 of 5 patients died at 26 months after diagnosis of thyroid metastases from breast cancer. Lacka et al[7] reported that one patient with thyroid metastases from breast cancer had metastases in liver, and lung at 5 months after thyroidectomy, and died at postoperative 36 months. Metastases in bone at 32 months after hemithyroidectomy were observed in a patient with thyroid metastases from breast cancer who died at postoperative 45 months[4].

**Conclusion**

We reported the rare case of thyroid metastases from breast carcinoma, which highlights that thyroid metastases should be considered in a patient with thyroid lesions in combination with a history of breast carcinoma. FNAB and IHC may contribute to distinguish thyroid metastasis from primary thyroid cancer.

**Abbreviations**

FNAB= fine needle aspiration biopsy, US= ultrasound, IHC= immunohistochemistry, GATA3=GATA-binding protein 3, HER2=human epidermal growth factor receptor 2, ER=estrogen receptor, PR=progesterone receptor, TTF1=thyroid transcription factor, TG=Thyroglobulin, GCDFP15=gross cystic disease fluid protein 15, CT= computed tomography, PAX8=paired box 8, HE=hematoxylin and eosin.

**Declarations**

**Consent**

This study was approved by the ethics committee of the West China Hospital, Sichuan University, and written informed consent was provided by the patient for publication of this case publication.

**Competing interests**

The authors declare that they have no competing interests

**Author contributions**

Yichao Wang and Shengliang Zhou contributed equally to this work. Tao Wei, Jingqiang Zhu and Zhihui Li designed the research. Yichao Wang, Shengliang Zhou, Boyang and Yu Ping Zhou developed the literature search. Yichao Wang and Shengliang Zhou drafted the article. All authors read and approved the final manuscript.

**Funding source**: This work was supported by Sichuan Science and Technology Program (No. 2019YJ0038)
Author details

1Department of Thyroid & Parathyroid Surgery Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. 2West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China. 3Department of Sonography, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China. 4Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China

References

[1] Zhou L, Chen L, Xu D, Shao Q, Guo Z, Ge M. Breast cancer metastasis to thyroid: a retrospective analysis. Afr Health Sci 2017;17:1035-1043.

[2] Magers MJ, Dueber JC, Lew M, Pang JC, Davenport RD. Metastatic ductal carcinoma of the breast to the thyroid gland diagnosed with fine needle aspiration: A case report with emphasis on morphologic and immunophenotypic features. Diagn Cytopathol 2016;44:530-534.

[3] Kim TY, Kim WB, Gong G, Hong SJ, Shong YK. Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. Clin Endocrinol (Oxf) 2005;62(2):236-241.

[4] Pensabene M, Stanzone B, Cerillo I, Ciancia G, Cozzolino I, Ruocco R, et al. It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. BMC Cancer 2018;18:146.

[5] Ghias AF, Epps G, Cottrill E, Mardekian SK. Multifocal Metastatic Breast Carcinoma to the Thyroid Gland Histologically Mimicking C Cell Lesions. Case Rep Pathol 2019;2019:9890716.

[6] Magers MJ, Dueber JC, Lew M, Pang JC, Davenport RD. Metastatic ductal carcinoma of the breast to the thyroid gland diagnosed with fine needle aspiration: A case report with emphasis on morphologic and immunophenotypic features. Diagn Cytopathol 2016;44(6):530-534.

[7] Lacka K, Breborowicz D, Uliasz A, Teresiak M. Thyroid metastases from a breast cancer diagnosed by fine-needle aspiration biopsy. Case report and overview of the literature. Exp Oncol 2012;34(2):129-133.

[8] Gerges AS, Shehata SR, Gouda IA. Metastasis to the thyroid gland; unusual site of metastasis. J Egypt Natl Canc Inst 2006;18:67-72.

[9] Hegerova L, Griebeler ML, Reynolds JP, Henry MR, Gharib H. Metastasis to the thyroid gland: report of a large series from the Mayo Clinic. Am J Clin Oncol 2015;38:338-42.

[10] Wood K, Vini L, Harmer C. Metastases to the thyroid gland: the Royal Marsden experience. Eur J Surg Oncol 2004;30(6):583-588.
[11] Owens CL, Basaria S, Nicol TL. Metastatic breast carcinoma involving the thyroid gland diagnosed by fine-needle aspiration: a case report. Diagn Cytopathol 2005;33:110-115.

[12] Baloch Z, Mete O, Asa SL. Immunohistochemical Biomarkers in Thyroid Pathology. Endocr Pathol 2018;29:91-112.

[13] Gabsi A, El Amine El Hadj O, Goucha A, Said G, Laabidi B, Gamoudi A. Clinico-pathological and prognostic findings on 27 cases of medullary thyroid carcinoma. Tunis Med 2017;95:97-102.

[14] Wagner K, Arciaga R, Siperstein A, Milas M, Warshawsky I, Sethu S, et al. Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnostic synergy for detecting thyroid cancer. J Clin Endocrinol Metab 2005;90:1921-1924.

[15] Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C, et al. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. Hum Pathol 2016;47:26-31.

[16] Kandalaft PL, Simon RA, Isacson C, Gown AM. Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections. Appl Immunohistochem Mol Morphol 2016;24:609-614.

[17] Ni YB, Tsang JYS, Shao MM, Chan SK, Cheung SY, Tong J, et al. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. Breast Cancer Res Treat 2018;169:25-32.

[18] El Hag MI, Hag AM, Ha JP, Michael CW. Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study. Pleura Peritoneum 2017;2:143-148.

[19] Bourcier K, Fermeaux V, Lebon S, Deluche E. Lobular Breast Carcinoma Metastasis to the Thyroid Gland: Case Report and Literature Review. J Breast Cancer 2018;2:463-467.

[20] Calzolari F, Sartori PV, Talarico C, Parmegiani D, Beretta E, Pezzullo L, et al. Surgical treatment of intrathyroid metastases: preliminary results of a multicentric study. Anticancer Res 2008;28:2885-2888.

[21] Chung AY, Tran TB, Brumund KT, Weisman RA, Bouvet M. Metastases to the thyroid: a review of the literature from the last decade. Thyroid 2012;22:258-268.

Figures
Figure 1

Ultrasound of thyroid showed heterogeneous enlargement and diffuse scattered microcalcifications (A), and enlarged cervical lymph nodes (B).

Figure 2

Hematoxylin and eosin (HE) stained FNAB of the right thyroid lobe (A, 200× magnification) and left thyroid lobe (B, 200× magnification) revealed malignant epithelial cells.
Figure 3

IHC staining showed that malignant cells in thyroid were positive for GATA3 (A, 200× magnification) and HER2 (B, 200× magnification), and negative for TTF1(C, 200× magnification), TG (D, 200× magnification).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CAREchecklistEnglish.docx